PAM
ARGS

Paradigm Asset Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Paradigm Asset Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-180
Closed -$28.9K – 921
2014
Q2 		$28.9K Buy
+180
New +$29.8K ﹤0.01% 765

Other funds holding ARGS

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Caisse de Depot et Placement du Quebec (CDPQ)
Caisse de Depot et Placement du Quebec (CDPQ) Montreal, Quebec, Canada $62.4B AUM 23.7% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PSI
Pinnacle Summer Investments Fairfax, Virginia $678M AUM 9.54% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Paradigm Asset Management's ARGS Position: Q3 2014 in Review

Paradigm Asset Management sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2014, closing a stake of 180 shares — an estimated $28.9K sold.

Paradigm Asset Management first reported a position in ARGS in Q2 2014 and held it in 1 quarter. The position peaked at $28.9K in Q2 2014. 26 funds tracked by Wall St. Rank hold ARGS as of Q3 2014.

  • Paradigm Asset Management reported no remaining Argos Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • Paradigm Asset Management sold 180 Argos Therapeutics, Inc. shares in Q3 2014, an estimated $28.9K.
  • Paradigm Asset Management first reported a position in Argos Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • Paradigm Asset Management's Argos Therapeutics, Inc. position peaked at $28.9K in Q2 2014.
  • 26 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2014.

Based on Paradigm Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.